Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine

Cellular Immunology

Volumn 261, Issue 2, 2010, Pages 93-98

  Memarnejadian, Arash ^a   Roohvand, Farzin ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

CTL response; DNA vaccine; Hepatitis B surface antigen; Hepatitis C virus; Polytope vaccine; Prime boost

Indexed keywords

CE4E6N PEPTIDE PLUS CPG 1826 PLUS MONTANIDE ISA 720; CE4E6N POLYTOPE; CE4E6N POLYTOPE HBSAG FUSION PROTEIN; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HYBRID PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; FEMALE; HEPATITIS C VIRUS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TH1 CELL; TUMOR;

ANIMALS; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

HEPATITIS C VIRUS; MUS;

EID: 77649184813     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.11.005     Document Type: Article

References (34)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
2. Pawlotsky J.M. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:383-385.
3. Moradpour D., Brass V., Gosert R., Wolk B., Blum H.E. Hepatitis C: molecular virology and antiviral targets. Trends Mol. Med. 2002, 8:476-482.
4. Penin F. Structural biology of hepatitis C virus. Clin. Liver Dis. 2003, 7:1-21.
5. Dustin L.B., Rice C.M. Flying under the rader: the immunobiology of hepatitis C. Annu. Rev. Immunol. 2007, 25:71-99.
6. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5:215-229.
7. Gurunathan S., Klinman M.D., Seder A.R. DNA vaccines: immunology, application and optimization. Annu. Rev. Immunol. 2000, 18:927-974.
8. Sarobe P., Lasarte J.J., Casares N., Lopez-Diaz de C.A., Baixeras E., Labarga P., Garcia N., Borràs-Cuesta F., Prieto J. Abnormal priming of CD4(+) T-cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol. 2002, 76:5062-5070.
9. Shi L., Liu S., Fan G., Sheng L., Ren H., Yuan Y. Effective induction of type-1 cytotoxic T-cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T-lymphocyte epitopes. Viral Immunol. 2006, 19:702-711.
10. Sette A., Livingston B., McKinney D., Appella E., Fikes J., Sidney J., Newman M., Chesnut R. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 2001, 29:271-276.
11. Suhrbier A. Polytope vaccines for the co-delivery of multiple CD8 T-cell epitopes. Expert Rev. Vaccines 2002, 1:207-213.
12. Chen L., Gao T., Yang N., Huang J., Chen Y., Gao T., Li Q., Ren D. Immunization with a synthetic multi-epitope antigen induces humoral and cellular immune responses to hepatitis C virus in mice. Viral Immunol. 2007, 20:170-179.
13. Martin P., Simon B., Lone Y.C., Chatel L., Barry R., Inchauspé G., Fournillier A. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008, 26:2471-2481.
14. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., Thomson S.A., Ffrench R.A., Elliott S.L., Firat H., Lemonnier F.A., Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA-A2 HIV CD8+ cytotoxic T-cell epitopes. J. Virol. 1999, 73:5320-5325.
15. Radcliffe J.N., Roddick J.S., Friedmann P.S., Stevenson F.K., Thirdborough S.M. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J. Immunol. 2006, 177:6626-6633.
16. Jin H., Kang Y., Xiao C., Zhu K., Ma Y., Xie Q., Ma J., Xie Q., He C., Yang Z., Sun Z., Zhang X., Chen M., Zhang F., Wang B. DNA-prime followed by protein-boost enhances neutralization and Th1-type immunity against FMDV. Viral Immunol. 2005, 18:539-548.
17. Bellier B., Delba C., Clerc B., Desjardins D., Drury R., Cosset F., Collins M., Klatzmann D. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006, 24:2643-2655.
18. Marsac D., Puaux A.L., Riviere Y., Michel M.L. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice. Immunobiology 2005, 210:305-319.
19. Woo W.P., Doan T., Herd K., Netter H.J., Tindle R. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J. Virol. 2006, 80:3975-3984.
20. Memarnejadian A., Roohvand F., Arashkia A., Rafati S., Shokrgozar M.A. Polytope DNA vaccine development against hepatitis C virus: A streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept. Lett. 2009, 16:842-850.
21. Lohr H.F., Schmitz D., Arenz M., Weyer S., Gerken G., Meyer zum Büschenfelde K.H. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T-cell frequencies. J. Hepatol. 1999, 31:407-415.
22. Park S.H., Yang S.H., Lee C.G., Youn J.W., Chang J., Sung Y.C. Efficient induction of T helper-1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 2003, 21:4555-4564.
23. Sarobe P., Huarte E., Lasarte J.J., de Cerio L., Garcia N., Borràs-Cuesta F., Prieto J. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2-restricted cytotoxic T-lymphocytes. J. Hepatol. 2001, 34:321-329.
24. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001, 194:1395-1406.
25. Roohvand F., Aghasadeghi M.R., Sadat S.M., Budkowska A., Khabiri A.R. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem. Biophys. Res. Commun. 2007, 354:641-649.
26. Shinoda K., Xin K.Q., Jounai N., Kojima Y., Tamura Y., Okada E., Kawamoto S., Okuda K., Klinnman D., Okuda K. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Vaccine 2004, 22:3676-3690.
27. Sprecher E., Becker Y. Herpes simplex virus type 1 pathogenicity in footpad and ear skin of mice depends on langerhans cell density, mouse genetics, and virus strain. J. Virol. 1987, 61:2515-2522.
28. Jazayeri M., Soleimanjahi H., Fotouhi F., Pakravan N. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice. Comp. Immunol. Microbiol. Infect. Dis. 2009, 32:453-461.
29. Boyle J.S., Koniaras C., Lew A.M. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T-lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int. Immunol. 1997, 9:1897-1906.
30. Baez-Astua A., Herraez-Hernandez E., Garbi N., Pasolli H.A., Juarez V., Zur H.H., Cid-Arregui A. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type-16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J. Virol. 2005, 79:12807-12817.
31. Jin J., Yang J., Liu J., Kong Y., Wang Y., Li G. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV. World J. Gastroenterol. 2002, 8:505-510.
32. Netter H.J., Macnaughton T.B., Woo W.P., Tindle R. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol. 2001, 75:2130-2141.
33. Qiu Q., Wang R.Y., Jiao X., Jin B., Sugauchi F., Grandinetti T., Alter H.J., Shih J.W. Induction of multi-specific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 2008, 26:5527-5534.
34. Welsh R.M., McNally J.M., Brehm M.A., Selin L.K. Consequences of cross-reactive and bystander CTL responses during viral infections. Virology 2000, 270:4-8.